KPV
Lys-Pro-Val (α-MSH C-terminal tripeptide, residues 11-13)
Access and compounding status raise extra safety and legal questions; current FDA review is active.
A tiny fragment of a natural hormone that has shown strong anti-inflammatory effects in the gut in laboratory and animal studies, by blocking a key inflammation pathway inside intestinal cells. No human clinical trials have been published, so its safety and effectiveness in people are not yet known.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Safety Summary
No systematic human safety database, pharmacovigilance series, or controlled trial safety dataset for KPV is present in the ledger.(U.S. Food and Drug Administration) (PMID 23940690) Route-specific human safety (oral, topical, intranasal, subcutaneous, intravenous) for KPV is not characterized in any ledger source; absence of reported adverse events in small preclinical work cannot be interpreted as a safety signal.(PMID 23940690) (PMID 18346897) Immunogenicity, peptide impurities, API characterization, sterility, concentration, gray-market product identity, long-term safety, special-population data, and drug/condition interactions for KPV are not addressed in the ledger; the FDA bulk-substances context explicitly raises peptide characterization and impurity concerns for compounded peptides generally.(U.S. Food and Drug Administration) Theoretical mechanism-linked risk arises from KPV's relationship to the alpha-MSH/melanocortin pathway (immune-modulatory and pigmentary signaling) but no human risk quantification is provided in the ledger.(PMID 23940690) (PMID 6332195)
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-12]